Skip to main content
Clinical Trials/NCT06696651
NCT06696651
Not yet recruiting
Not Applicable

Electrical Muscle Stimulation Effect Compared With Myofascial Release on Quality of Life in Female Fibromyalgia

Cairo University1 site in 1 country60 target enrollmentDecember 15, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Electric Stimulation
Sponsor
Cairo University
Enrollment
60
Locations
1
Primary Endpoint
Assessment of change of body mass index
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

the study was done to investigate the effect of Electrical Muscle Stimulation as muscle strengthening versus the effect of myofascial releasing on quality of life in female fibromyalgia patients while following Mediterranean diet.

Detailed Description

Fibromyalgia is a chronic pain condition characterized by unrefreshing sleep, physical exhaustion, and cognitive difficulties. It affects all populations worldwide and requires a diagnosis of widespread pain for at least three months. People with Fibromyalgia show abnormal endogenous pain modulation, including reduced conditioned pain modulation and exercise-induced hypoalgesia. Exercise is considered a first-line treatment for Fibromyalgia. Electrical myostimulation has been shown to improve pain, sleep subscales, and quality of life. A potential causal link between Fibromyalgia and micronutrient deficiency has been suggested. The study focuses on fibromyalgia, which affects mostly females and is difficult to diagnose easily. Electrical myostimulation and myofascial release are effective treatments for Fibromyalgia.

Registry
clinicaltrials.gov
Start Date
December 15, 2024
End Date
March 15, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Maha Mostafa Osman

principal investigator

Cairo University

Eligibility Criteria

Inclusion Criteria

  • Sixty females have diagnosed suffering from fibromyalgia syndrome.
  • Their ages will be ranged from 45 to 55 years old.
  • Their body mass index will be ranged from 25 to 34 ( overweight and obese type 1)
  • They have willingness to participate in this study.

Exclusion Criteria

  • Peripheral vascular diseases.
  • Drug abuse.
  • Chest disease. ( either obstructive or restrictive ).
  • Clinical signs of sever cardiac events ( eg. Congestive heart disease).

Outcomes

Primary Outcomes

Assessment of change of body mass index

Time Frame: at baseline and after 6 weeks

to measure body weight and height to calculate BMI for characterizing the sample.

Assessment of change of pressure pain threshold using algometry

Time Frame: at baseline and after 6 weeks

Algometry is a useful tool for assessing central allodynia and hyperalgesia in FM and other pain conditions. It can provide insights into psychological factors influencing pain experience, new dynamic pain indicators, and neuroimaging techniques.

Secondary Outcomes

  • assessment of fibromyalgia using Fibromyalgia Impact Questionnaire(at baseline and after 6 weeks)

Study Sites (1)

Loading locations...

Similar Trials